$LQDA

Bloch Stephen M sold $14.3M of LQDA (indirect holdings)

Bloch Stephen M sold 220,835 indirectly-held shares of Liquidia Corp (LQDA) at an average of $64.64 ($64.27–$66.19, $14.27M total) across 5 trades over 2026-06-08 to 2026-06-09.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosure provides incremental sentiment information (insider reducing holdings) but lacks any accompanying fundamental update.

02

Market read

Traders may monitor for follow-on insider activity or whether the sale coincides with other company-specific catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The filing shows indirect ownership and multiple trades; without stated rationale, traders may overinterpret the signal versus broader price/volume trends.

Relevance 7/10Novelty 5/10Timing: Filed 2026-06-10; transactions dated 2026-06-08 to 2026-06-09.

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.27M of LQDA shares via open-market transactions (Form 4), reducing insider exposure.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The article is a primary-source insider transaction (Form 4) with sizable dollar value, but it does not include earnings, guidance, clinical, regulatory, or deal information that would reprice the business.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect negative company outlook, especially without a disclosed 10b5-1 plan context.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Stephen M. Bloch

    Director who sold 220,835 shares of LQDA for ~$14.27M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.